3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
3
Neoplasms
3
Breast Neoplasms
3
Pain
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Incontinence, Stress
1
Urinary Incontinence
1
Sleep Initiation and Maintenance Disorders
1
Postoperative Urinary Retention (POUR)
1
Postoperative Nausea and Vomiting
1
Postoperative Complications
1
PGS
1
Opioid-Induced Constipation
1
Neuropathy, Painful
1
Neuralgia
1
Multiple Endocrine Neoplasia Type 1
1
Low Anterior Resection Syndrome
1
Fatigue
1
Depression
1
Cancer Pain
1
Anxiety Disorders
1
Agnosia
1
Interventions
Bupivacaine
4
Saline Solution
3
Ketamine
3
Transcutaneous Electric Nerve Stimulation
2
Ropivacaine
2
Radiofrequency Ablation
2
Magnesium Sulfate
2
Ketorolac
2
Dexmedetomidine
2
Control Groups
2
Anesthesia, Local
2
Acupuncture Therapy
2
Acetaminophen
2
engage 8200
1
Yoga
1
Varenicline
1
Transdermal Patch
1
Therapeutics
1
Telemedicine
1
Surgical Instruments
1
STAMP-I protocol
1
Radiosurgery
1
Psilocybin
1
Palliative Care
1
Oxycodone
1
Music Therapy
1
Morphine
1
Methods
1
Levobupivacaine
1
Ketoprofen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Agnosia
×
Electroacupuncture
×
1 year
×
Clear all
NCT04917796
2026-01-30
ACT
Dana-Farber Cancer Institute
Phase NA
Active not recruiting
255 enrolled